pharmaphorum19h
Novo Nordisk asks FDA not to allow GLP-1 compounding
Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...
pharmaphorum19h
Novo Nordisk grabs NASH drug from Ventus in $703m deal
The deal adds to a rapidly-expanding pipeline of NASH candidates at Novo Nordisk, which also includes GLP-1 analogue semaglutide in phase 3 in combination with drugs from Gilead, a long-acting ...